Plain-English translation of NCT06445062 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether and —two new experimental medications—work better when combined with standard cancer treatments for people with advanced colorectal or pancreatic cancer. The study focuses on cancers that have specific RAS gene mutations, which are changes that can affect how cancer grows. Researchers want to find the right doses and combinations of these medications to help fight these difficult-to-treat cancers.
Many people with advanced colorectal and pancreatic cancer have RAS mutations, which makes their tumors harder to treat with existing therapies. This medication targets these specific genetic changes in a new way, and early research suggests combining it with current standard treatments might help more patients respond to therapy.
You likely qualify if…
You likely don't qualify if…
You would take the experimental medication by mouth, usually once or twice daily, along with standard chemotherapy drugs given by infusion or other methods. You'll visit the study center regularly so doctors can monitor your health, check how well the treatment is working, and watch for any side effects through blood tests and scans. The exact length of treatment depends on how your cancer responds and how well you tolerate the medication, but you can expect multiple clinic visits over several months.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States